VVOS - Latest News
Vivos Therapeutics, Inc. (VVOS), operates in Healthcare / Medical - Devices, trades on NASDAQ.
Market capitalization stands near $3.6M. Beta to the broader market is 6.21.
The article list below shows the most recent VVOS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent VVOS Headlines
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
seekingalpha.com - May 21, 2026
Vivos Therapeutics, Inc.
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
globenewswire.com - May 20, 2026
Year-over-year revenue increased 70%, reflecting contribution from Vivos' acquisition of The Sleep Center of Nevada Management to Host Conference Call
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
invezz.com - May 9, 2026
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets,
Vivos Therapeutics Q4 Earnings Call Highlights
defenseworld.net - Apr 17, 2026
Vivos Therapeutics (NASDAQ: VVOS) executives told investors the company's shift toward a medical provider-focused model, anchored by the June 2025 acq
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
seekingalpha.com - Apr 15, 2026
Vivos Therapeutics, Inc.
How News Affects VVOS Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track VVOS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked VVOS news questions
- What is the latest VVOS news headline?
- The most recent VVOS headline (May 21, 2026) is "Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the VVOS news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What VVOS news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual VVOS options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.